Table 2

Disease characteristics of patients with systemic lupus erythematosus (SLE) in highest quartile leptin levels compared with lowest three quartiles

Highest quartile leptin (≥29.5 ng/ml)Lowest three quartiles leptin (<29.5 ng/ml)
Characteristicsn=61n=189p Value
Age (years, (mean±SD))44.7±13.441.8±12.5NS
History of hypertension (% (n))31.1 (19)30.7 (58)NS
History of diabetes (% (n))4.9 (3)5.3 (10)NS
History of smoking (current) (% (n))6.6 (4)7.9 (15)NS
History of previous cardiovascular disease (% (n))14.8 (9)6.3 (12)0.04
Body mass index28.5±7.125.5±6.10.001
Family history of CAD (% (n))19.7 (12)26.5 (50)NS
Previous history of glomerulonephritis (%(n))18.0 (11)28.0 (53)NS
Total cholesterol (mg/dl, (mean±SD))196.0±48.5184.4±42.1NS
HDL (mg/dl, (mean±SD))58.0±17.856.4±16.7NS
LDL (mg/dl, (mean±SD))115.4±39.0105.3±34.10.08
Triglycerides (mg/dl, (mean±SD))113.3±68.4110.2±67.7NS
History of dyslipidaemia19.7 (12)15.3 (29)NS
Disease duration (years, (mean±SD))12.9±9.212.2±8.0NS
SELENA-SLEDAI (mean±SD)3.8±3.44.0±4.1NS
SDI damage (mean±SD)1.48±1.51.2±1.60.04
Intima-media thickness (mm2, (mean±SD))0.57±0.140.54±0.14NS
Presence of carotid plaque (yes, no) (% (n))29.5 (18)13.2 (25)<0.003
Number of plaques (mean±SD)0.61±1.20.30±0.950.004
High sensitivity CRP (mean±SD)4.04±11.12.4±4.8NS
Non-Caucasian ethnicity (% (n))26.2 (16)22.8 (43)NS
Current medication (% (n))
 Mycophenolate mofetil19.7 (12)23.3 (44)NS
 Hydroxychloroquine59.0 (36)62.4 (118)NS
 Cyclophosphamide3.3 (2)0.5 (1)NS
 Azathioprine6.6 (4)13.8 (26)NS
Current prednisone (mg, (mean±SD))4.8±9.14.3±7.7NS
6-Month prednisone (mg, (mean±SD))687.0±1041.1821.7±1304.8NS
Lp(a) (mg/dl)24.9±25.916.9±9.70.01
OxPL/apoB100 (RLU)22035.1±24583.313895.1±18182.10.02
Proinflammatory HDL (% (n))60.7 (37)49.2 (93)<0.001
  • CAD, coronary artery disease; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OxPL/apoB100, oxidised phospholipids on apoB100; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SELENA, Safety of Estrogens in Lupus Erythematosus—National Assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; RLU, relative light units